Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Theracor is derived from human umbilical cord extracellular matrix (ECM) and is designed to cover, protect, and maintain a moist wound environment
Subscribe To Our Newsletter & Stay Updated